Maryam Latarani

Maryam Latarani

Auto-generated profile, based on publicly available information

Maryam Latarani

Cancer Research Group, School of Life Health and Chemical Sciences, The Open University UK, Milton Keynes MK7 6AA, UK

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Epigenomics
Verified
Journal Article
Open access
NKNing Kang
Ning Kang
MEMark Eccleston
Mark Eccleston
PCPier-Luc Clermont
Pier-Luc Clermont
MLMaryam Latarani
Maryam Latarani
DMDavid Male
David Male
FCFrancesco Crea
Francesco Crea
Immunotherapies are revolutionizing the clinical management of a wide range of cancers. However, intrinsic or acquired unresponsiveness to immunotherapies does occur due to the dynamic cancer immun...

27 April 2022 in Epigenomics
Verified
Journal Article
Open access
FSFrancesca Salani
Francesca Salani
MLMaryam Latarani
Maryam Latarani
AGAndrea Casadei gardini
Andrea Casadei gardini
PGPriyadarsini Gangadharannambiar
Priyadarsini Gangadharannambiar
LFLorenzo Fornaro
Lorenzo Fornaro
FCFrancesco Crea
Francesco Crea
Background: Predictive biomarkers for advanced hepatocellular carcinoma are lacking. EZH2 drives sorafenib resistance through H3K27me3 and is counteracted by SETD2, which catalyzes H3K36me3. The au... Plain language summary Hepatocellular carcinoma (HCC) is responsible for approximately 10% of all cancer-related deaths worldwide. It is caused mainly by dysmetabolic syndrome, which is the presenc...

11 September 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
MLMaryam Latarani
Maryam Latarani
PPPerla Pucci
Perla Pucci
MEMark Eccleston
Mark Eccleston
MMMassimiliano Manzo
Massimiliano Manzo
PGPriyadarsini Gangadharannambiar
Priyadarsini Gangadharannambiar
FCFrancesco Crea
Francesco Crea
Background: EZH2 promotes aggressive-variant prostate cancer (AVPC) progression via histone H3-Lysine-27 tri-methylation (H3K27me3). We hypothesize that epigenetic reprogramming via EZH2 inhibitors (EZH2i) improves the efficacy of chemotherapy in AVPC. Methods: We studied the expression of EZH2 in clinical prostate cancer cohorts (bioinformatics). We determined the effect of EZH2i on both cellular- and cell-free-H3K27me3 levels. We measured effects of carboplatin with/without EZH2i on AVPC cell viability (IC 50 ). We studied how EZH2i modulate gene expression (RNA Seq). Results: EZH2 was significantly up-regulated in AVPC vs other prostate cancer types. EZH2i reduced both cellular and cell free-H3K27me3 levels. EZH2i significantly reduced carboplatin IC 50 . EZH2i reduced the expression of DNA repair and increased the expression of pro-apoptotic genes. Article Highlights: Polycomb-mediated gene silencing promotes prostate cancer progression Aggressive-variant prostate cancers (AVPCs) are characterized by increased activity of the Polycomb-Repressive Complex 2 (PRC2) Here we show that PRC2 inhibitors are scarcely effective as monotherapy in ACPC cells However the combination of PRC2 inhibitors and carboplatin is highly synergistic RNA Seq studies revealed that PRC2 inhibitors enhance carboplatin activity by modulating several key pathways, including DNA repair and apoptosis.